VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection

Completed

Conditions: HIV Infections

Interventions: Other: Functional Assessment of HIV Infection
Other: Patient Satisfaction Questionnaire
Other: Symptom Distress Module
Other: Patient Health Questionnaire
Other: Internalized Stigma of AIDS Tool
Other: Medication adherence visual analogue scale

First Posted Date: 2018-01-17

Last Posted Date: 2019-03-11

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 1184

Registration Number: NCT03400293

Locations: 🇺🇸
GSK Investigational Site, Arlington, Virginia, United States

PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)

Completed

Conditions: Infection, Human Immunodeficiency Virus I

Interventions: Drug: DTG based ARV regimen with ABC
Drug: RAL or EGV based regimens without ABC
Drug: Any other DTG based ARV regimen as monotherapy
Drug: DTG based ARV regimen without ABC
Drug: RAL or EGV based ARV regimens with ABC

First Posted Date: 2017-10-31

Last Posted Date: 2020-02-06

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 1

Registration Number: NCT03327740

Phase 4 Study of Dolutegravir (DTG) in Russian Federation

Phase 4

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Dolutegravir 50 mg

First Posted Date: 2017-10-19

Last Posted Date: 2019-02-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 43

Registration Number: NCT03314064

Locations: 🇷🇺
GSK Investigational Site, Toliyatti, Russian Federation

Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men

Completed

Conditions: HIV Infections
Infection, Human Immunodeficiency Virus

Interventions: Behavioral: Risk reduction counseling
Other: Social harm interview
Other: Computer-Assisted Self Interviewing technique

First Posted Date: 2017-10-16

Last Posted Date: 2020-03-12

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 578

Registration Number: NCT03310515

Locations: 🇨🇳
GSK Investigational Site, Shenzhen, China

Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Phase 3

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: Cabotegravir Tablets
Drug: Rilpivirine Injectable Suspension
Drug: Rilpivirine Tablets
Drug: Cabotegravir Injectable Suspension

First Posted Date: 2017-10-02

Last Posted Date: 2024-12-27

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 1049

Registration Number: NCT03299049

Locations: 🇸🇪
GSK Investigational Site, Stockholm, Sweden

GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infections
Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK3640254
Drug: Placebo

First Posted Date: 2017-07-27

Last Posted Date: 2021-06-10

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 78

Registration Number: NCT03231943

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus
HIV Infections

Interventions: Drug: Cabotegravir
Drug: Rifabutin

First Posted Date: 2017-05-11

Last Posted Date: 2020-09-17

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 15

Registration Number: NCT03149848

Locations: 🇬🇧
GSK Investigational Site, Cambridge, United Kingdom

Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Conventional dolutegravir 10 mg tablet
Drug: Dispersible dolutegravir 5 mg tablet
Drug: Conventional dolutegravir 50 mg tablet
Drug: Conventional dolutegravir 25 mg tablet

First Posted Date: 2017-03-29

Last Posted Date: 2019-07-23

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 38

Registration Number: NCT03095638

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Phase 1

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Dolutegravir
Drug: Lamivudine
Drug: Dolutegravir + Lamivudine FDC Formulation 1
Drug: Dolutegravir + Lamivudine FDC Formulation 2

First Posted Date: 2017-03-13

Last Posted Date: 2019-02-21

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 154

Registration Number: NCT03078556

Locations: 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States

Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019

Phase 3

Active, not recruiting

Conditions: HIV Infections

Interventions: Drug: Dolutegravir film-coated tablets
Drug: ABC/DTG/3TC immediate release tablets
Drug: Dolutegravir film-coated dispersible tablets
Drug: ABC/DTG/3TC film-coated dispersible tablets

First Posted Date: 2017-01-10

Last Posted Date: 2024-02-15

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 101

Registration Number: NCT03016533

Locations: 🇿🇼
GSK Investigational Site, Harare, Zimbabwe

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy